These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26329608)

  • 21. Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.
    D'Alessandro R; Messa C; Refolo MG; Carr BI
    Expert Opin Pharmacother; 2015; 16(18):2773-80. PubMed ID: 26479083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
    Carr BI; Cavallini A; Lippolis C; D'Alessandro R; Messa C; Refolo MG; Tafaro A
    J Cell Physiol; 2013 Feb; 228(2):292-7. PubMed ID: 22777740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.
    Mirone G; Perna S; Shukla A; Marfe G
    J Cell Physiol; 2016 May; 231(5):1097-105. PubMed ID: 26419617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
    Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
    Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.
    Mayer B; Karakhanova S; Bauer N; Liu L; Zhu Y; Philippov PP; Werner J; Bazhin AV
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Nov; 390(11):1125-1134. PubMed ID: 28779210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells.
    Hsu FT; Sun CC; Wu CH; Lee YJ; Chiang CH; Wang WS
    Anticancer Res; 2017 Sep; 37(9):4919-4926. PubMed ID: 28870913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2018; 211():45-56. PubMed ID: 30069758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines.
    Refolo MG; D'Alessandro R; Lippolis C; Carella N; Cavallini A; Messa C; Carr BI
    Oncotarget; 2017 Nov; 8(61):103465-103476. PubMed ID: 29262576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
    Eustace AJ; Crown J; Clynes M; O'Donovan N
    J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction.
    Wang R; Liu Y; Mi X; Chen Q; Jiang P; Hou J; Lin Y; Li S; Ji B; Fang Y
    Arch Biochem Biophys; 2020 Aug; 689():108415. PubMed ID: 32562663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
    Breitkreutz I; Podar K; Figueroa-Vazquez V; Wilhelm S; Hayden PJ; Anderson KC; Raab MS
    Ann Hematol; 2018 May; 97(5):839-849. PubMed ID: 29359239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.
    Zopf D; Fichtner I; Bhargava A; Steinke W; Thierauch KH; Diefenbach K; Wilhelm S; Hafner FT; Gerisch M
    Cancer Med; 2016 Nov; 5(11):3176-3185. PubMed ID: 27734608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regorafenib for cancer.
    Strumberg D; Schultheis B
    Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.